Pre-Session Views
Update: 2025-10-23
Description
- Strategy | We are buyers of every dip in Memphis PharmaWe are buyers of every dip in Memphis Pharma
- RAYA/RACC | RAYA/RACC acquisition is now most likely to go through at RAYA’s revised price of EGP9.0/share, exactly at the midpoint of our previously communicated price range
- PHAR | EIPICO III delay extends visibility gap, rotation toward MPCI and RMDA
- AMOC | Shareholder rotation reflects profitability headwinds
- EGAL | Riding the aluminum wave
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
